natgillin/translations-raw huggingface dataset:
an agent for modulating adipokines or hormones of obesity, optionally leptin, ghrelin, resistin, adiponectin, chemerin, II-6, visfatin, retinal binding protein 4 or plasminogen activator inhibitor-1; 
(e) agens za moduliranje adipokina ili hormona pretilosti, opcionalno leptin, grelin, rezistin, adiponektin, kemerin, Il-6, visfatin, protein 4 koji veže retinol ili inhibitor aktivnosti plazminogena-1;
A device for intranasal or inhalational administration comprising the vaccine formulation according to claim 12 and a mechanism for aerosolization of the vaccine. 
Naprava za intranazalno ili inhalacijsko davanje naznačena time da sadrži formulaciju cjepiva prema zahtjevu 12 i mehanizam za aerogolizaciju cjepiva.
A 3B,5a,6B-trihydroxyl steroid compound having formula A or a pharmaceutically acceptable salt thereof for use in prophylaxis or treatment of an altitude sickness caused by hypobaric hypoxia: wherein R1 is H, a linear or branched alkyl or terminal alkenyl having 1 to 5 carbon atoms, or -CH(CH3)(CH2)3CH(CH3)2. 
M4 =: (Formula A) naznačena time, što RI je H, linearni ili razgranati alkil ili terminalmi alkil koji ima 1 do 5 atoma ugljika ili - CI(CH3X(CH2)sCH(CHs)2.
In another embodiment the marker vaccine of the present invention is characterised in that subjects treated with the vaccine as described herein can be differentiated from subjects infected with disease-associated swine fever virus via analysis of biological samples obtained from said subjects using serological and/or genomic analytical methods. 
8. Marker cjepivo skladu s bilo kojim prethodnim patentnim zahtjevom, naznačeno time što se subjekti tretirani cjepivom mogu razlikovati od subjekata zaraženih virusom svinjske groznice povezanim s bolešću analiziranjem biološkog uzorka dobivenog od navedenih subjekata koristeći serološke i/ili genomske analitičke metode.
A pharmaceutical composition comprising a compound as defined in any of claims 1 to 17, and one or more pharmaceutically acceptable excipients. 
Farmaceutski pripravak, naznačen time što sadrži spoj u skladu bilo kojim od patentnih zahtjeva 1 do 17, kao i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
Biodegradable composition according to Claim 4, wherein the heterocyclic aromatic compound is 2,5-furandicarboxylic acid. 
Biorazgradljivi pripravak prema zahtjevu 4, naznačen time da heterociklički aromatski spoj je 2,5furandikarboksilna kiselina.
2 a shows a cross-section of the central line section 32 of the line 13 with a first line part 30 and a second line part 31 . 
Slika 21 prikazuje presjek središnjeg dijela 32 cijevi 13 s prvim dijelom cijevi 30 i drugim dijelom cijevi 31.
A solid oral pharmaceutical formulation of claim 1, which comprises: 
Kruta oralna farmaceutska formulacija, naznačena time što sadrži:
The cytotoxic agent according to claim 8 or 9, wherein 1 to 10 DM1 molecules are conjugated to a single antibody molecule via SMCC. 
Citotoksično sredstvo u skladu s patentnim zahtjevom 6 ili 7, naznačeno time što je 1 do 10 molekula DM1 konjugirano s jednom molekulom protutijela preko SMCC.
The salt according to claim 1, which salt is the hydrogen maleate salt of the compound of formula [I]. 
Sol u skladu s patentnim zahtjevom 1, naznačena time, što je to sol vodikovog maleata spoja formule [I].
The compound of claim 1, wherein the compound is: or a pharmaceutically acceptable salt, a stereoisomer, and/or an N-oxide thereof. 
OH >N OH o)0H O ili njegova farmaceutski prihvatljiva sol, stereoizomer, 1/ili N-oksid.
Furthermore, the method may according to the invention further comprise a step of filtrating water and water soluble organics from oil and water soluble salts in a first membrane-filter. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva, nadalje obuhvaća korak filtriranja tekućine u vodu i u vodi topive organske tvari iz ulja i u vodi topive soli u prvom membranskom filtru.
Device as claimed in claim 1 wherein said hydraulic unit comprises pumping means suitable for conveying the solution contained in said first tank into the subcutaneous area of the patient through said measuring cell. 
Uređaj prema patentnim zahtjevima 1 - 3, naznačen time što navedena hidraulična jedinica (24) sadrži sredstvo za pumpanje pogodno za prijenos otopine sadržane u navedenom prvom rezervoaru (23) u subkutano područje pacijenta pomoću navedene stanice (20) za mjerenje.
The steel according to claim 1, consisting of: 
Čelik prema patentnom zahtjevu 4 naznačen time što se sastoji od:
(f′) deprotecting the boronic acid moiety to form the compound of formula (XIV) or a boronic acid anhydride thereof. 
(f') deprotekcije grupe organoborne kiseline tako da se formira spoj formule (XIV) ili njegov anhidrid organoborne kiseline.
The mixture was washed with water and the organic phase was dried (Na2SO4) to give a brown foam that was purified by flash chromatography eluting with 10%-50% EtOAc/hexane to give the Intermediate 60 as a yellow foam (0.477 g, 14% yield). 
Smjesa je isprana vodom i organska faza je sušena (Na»SOx) da bi se dobila smeđa pjena koja je pročišćena pomoću flash kromatografije eluiranjem sa 10%-50% EtOAc/heksanom da bi se dobio Intermedijer 60 kao žuta pjena (0.477 g, 14% prinos).
a method of treating or preventing cancer relapse in a subject, the method comprising administering to the subject a therapeutically effective amount of the pharmaceutical composition; 
liječenju relapsa raka u subjekta, koje obuhvaća primjenu terapijski učinkovite količine spoja formule VIII subjektu; ili
The incorporation of the fatty acid derivative was also noticed in the change of coating properties. 
Ugradnja derivata masne kiseline je također opažena u promjeni svojstava prevlake.
AIDS (reverse transcriptase 
(inhibitor revrzne transkriptaze)
reacting said modified antibody with a linker-conjugate, wherein: 
reakcije navedenog modificiranog antitijela s konjugatom linkera, gdje:
It was an astounding discovery because no theoretical underpinning suggests any difference of Meldonium orotate or polybasic acid salts, which are also readily soluble in water, from other salts as to hygroscopicity. 
To je bilo začuđujuće otkriće, jer nema nijedne teorijske potpore koja bi ukazivala na bilo koju razliku meldonij orotata ili soli polibazičnih kiselina, koje su također brzo topive u vodi, u odnosu prema drugim solima, posebno u pogledu higroskopnosti.
The detailed procedure is described below: 42-O-(tert-Butyldinaethylsilyl)rapanaycin 
Detaljan postupak opisan je u nastavku: 42-O-(terc-butildimetilsililrapamicin
detecting the complex formed in step (i); and 
(11) detekciju kompleksa formiranog u koraku (1); 1
A liquid pharmaceutical composition according to claim 7, wherein the luteinising hormone (LH) is present at a concentration of at or about 300 IU/ml to at or about 750 IU/ml. 
Tekući farmaceutski pripravak prema zahtjevu 7 naznačen time da je lutenizirajući hormon (LH) prisutan u koncentraciji od ili oko 300 TU/ml do točno ili oko 750 IU/ml.
The pharmaceutical composition may be in the form of a transdermal patch. 
Farmaceutski sastav prema patentnom zahtjevu 4, naznačen time, da je formuliran za transdermalnu primjenu ili u obliku transdermalnog flastera.
The glutamic acid residue at position 570 of SEQ ID NO: 1, 7, 8 or at position 569 of SEQ ID NO:9 has been substituted by a conservative amino acid residue. 
(a) aminokiselinska sekvenca koja je fragment čiji se lanac aminokiselina proteže u sastavu aminokiselinskih ostataka od 1 do 860 ili od 2 do 860 iz SEQ ID NO:1, gdje:
The method was published by Kocsis P., Tarnawa I., Kovács Gy., Szombathelyi Zs., Farkas S., 2002; Acta Pharmaceut. 
Ovu metodu su objavili Kocsis P., Tarnawa I., Kovacs Gy., Szombathelyi Zs., Farkas S., 2002; Acta Pharmaceut.
The invention further provides methods of treating Alzheimer's disease as adjunctive therapy to acetylcholinesterase treatment comprising administering an effective daily dose of N-[2-(6-fluoro-1H-indol-3-yl)ethyl]-3-(2,2,3,3-tetrafluoropropoxy)benzylamine or a pharmaceutically acceptable salt to a patient in need of such treatment, wherein the effective daily dose administered to the patient is between about 30 and about 60 mg. 
dnevne doze N-(2-(6-fluoro-1H-indol-3-iljetil)-3-(2,2,3,3- tetrafluoropropoksi)benzilamina ili njegove farmaceutski prihvatljive soli pacijentu koji je u potrebi takvog liječenja, pri čemu djelotvorna dnevna doza primijenjena na pacijentu iznosi između 30 1 60 mg.
adding at least one stabilizer selected from carbohydrates, polyhydric alcohols, and PVP to an aqueous solution of a cephalosporin derivative; and 
(a) dodavanja manitola kao stabilizatora u vodenu otopinu cefalosporinskog derivata; i
The antibody active agent conjugate of claim 3, wherein the subject has an infection with a pathogenic agent. 
Konjugat aktivnog sredstva antitijela u skladu s patentnim zahtjevom 3, naznačen time, da subjekt ima infekciju patogenim agensom.
introducing into the pluripotent rat cells a large targeting vector (LTVEC) comprising an insert nucleic acid flanked by a 5′ homology arm homologous to a first nucleic acid sequence at the genomic locus of interest and a 3′ homology arm homologous to a second nucleic acid sequence at the genomic locus of interest to produce the targeted genetic modification via homologous recombination, wherein the sum total of the 5′ and the 3′ homology arms is at least 10 kb; and 
uvođenje u pluripotentnu štakorsku stanicu velikog vektora za ciljanje (LTVEC) koji sadrži ubačenu nukleinsku kiselinu flankiran s 5' homolognim dijelom komplementarno prvoj sekvenci nukleinske kiseline u genomskom lokusu od interesa i 3' homolognim dijelom komplementarno drugoj sekvenci nukleinske kiseline u genomskom lokusu od interesa, pri čemu je ukupan zbroj 5' i 3' homolognih dijelova najmanje 10 kb; i
Surprisingly, however, when 42-O-(D-fructosylcarbonyl)rapamycin or 42-O-(L-fucitolylcarbonyl)rapamycin were administered orally the level of rapamycin in the blood rose gradually to reach a maximum concentration at approximately 3 hours before gradually decreasing over time (FIG. 6). 
Iznenađujuće je, međutim, da kod oralne primjene 42-O-(D-fruktozilkarbonil)rapamicina ili 42-O-(L-fucitolilkarbonil)rapamicina razina rapamicina u krvi raste postupno da bi dosegla maksimalnu koncentraciju nakon približno 3 sata prije nego postupno počne opadati s vremenom (slika 6).
Samples were taken periodically for HPLC. 
Periodički su bili uzimani uzorci za HPLC.
at least one oligonucleotide comprising or consisting of a sequence selected from a group consisting of (1) SEQ ID NO: 6, 48, 62-64 and variants thereof, (2) SEQ ID NO: 6, 44-48 and variants thereof, (3) SEQ ID NO: 1, 12 -15 and variants thereof, or (4) SEQ ID NO: 92; 
najmanje jedan nukleotid koji obuhvaća ii se sastoji od sekvence odabrane iz skupine sastavljene (1) SEK ID BR: 6, 48, 62-64 i njene inačice, (2) SEK ID BR: 6, 44-48 i njene inačice, (3) SEK ID BR: 1, 12 -15 i njene inačice, ili (4) SEK ID BR: 92;
The liposome composition according to any one of Claims 5 to 8, wherein the concentration of said base is 1 to 300 mM. 
Liposomski pripravak prema bilo kojem od zahtjeva 1 do 6, naznačen time da je koncentracija navedene base 1 do 300 mM.
A compound selected from the group consisting of: and 
Spoj prema patentnom zahtjevu 1 izabran iz grupe koju čine:
In some embodiments, the antibody specific for IL-23 is the humanized or chimeric antibody. In further embodiments, the immune response is an inflammatory response including arthritis, psoriasis, and inflammatory bowel disease. 
Antitijelo ili antigen-vežući fragment istog iz Zahtjeva 1, naznačeno time, što se koristi za liječenje poremećaja odabranih iz grupe koja se sastoji od artritisa, psorijaze i upalne bolesti crijeva.
Process according to any of claims 21 to 24, characterised in that following pH modification, said silicate-containing product is separated from the liquid phase and dried, thereafter comprising less than 30 %, preferably less than 50 %, and more preferably less than 66 %, by weight of said hydrophobically modified polyalkyleneimine relative to the amount of hydrophobically modified polyalkyleneimine prior to pH modification. 
Proces prema bilo kojem od zahtjeva 21 do 24, naznačen time što nakon modifikacije pH, proizvod koji sadrži silikat se odvaja od tekuće faze 1 suši, nakon čega sadrži manje od 30%, poželjno manje od 50%, i najpoželjnije manje od 66% težine tog hidrofobno modificiranog polialkilenimina u odnosu na količinu hidrofobno modificiranog polialkilenimina prije modifikacije pH.
Besides from the anatomical-structural point of view, the large intestine is quite different from the small intestine also, and above all, from the functional point of view (Braga P C. Enteric microflora and its regulation. 
Osim sa strukturno anatomskog stajališta, debelo crijevo se od tankog crijeva značajno razlikuje posebno sa funkcionalnog gledišta (Braga PC. Enteric microflora and its regulation.
Method for manufacturing a prefabricated building element the method comprising the steps of: peeling a log in a lathe to form a veneer, wherein the thickness of the veneer is in the range from about 2.5 mm up to about 5 mm; 
PATENTNI ZAHTJEVI Postupak proizvodnje predproizvedenog građevnog elementa, gdje se postupak sastoji u koracima: - = ljuštenja klade blanjalicom kako bi se dobilo furnir, gdje je debljina furnira u rasponu od otprilike 2,5 mm do otprilike 5 mm;
A compound, wherein the compound is or salt thereof. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 6 or salt thereof. 
Farmaceutska kompozicija koja sadrži terapijski efikasnu količinu najmanje jednog spoja bilo kojeg od patentnih zahtjeva 1 do 6, i opcionalno dodatno sadrži najmanje jedan drugi terapijski agens.
The reaction mixture was quenched with ice water, diluted with dichloromethane and transferred to separatory funnel. 
Reakcija je ugašena ledenom vodom, razrijeđena diklorometanom i prenesena u lijevak za odjeljivanje.
A method of reducing the formation of ET-701 in a composition of ET-743, comprising freeze-drying a bulk solution that comprises ET-743 and a disaccharide to yield a composition according to claim 1 wherein said disaccharide is selected from sucrose, lactose and a combination thereof. 
Postupak prema patentnom zahtjevu 18, naznačen time što je ekteinascidin ET-743. 20. Postupak za smanjenje stvaranja ET-701 u obliku ET-743, naznačen time što obuhvaća sušenje zamrzavanjem otopine za punjenje koja sadržava ET-743 i disaharid.
insoluble active ingredients for example nifedipine; lipid soluble active ingredients for example gemfibrizol; and captopril; 
netopljivih aktivnih sastojaka, na primjer, nifedipina; lipid topljivih aktivnih tvari, na primjer gemfibrizola; i kaptoprila;
Rapamycin alone (U.S. Pat. No. 4,885,171) or in combination with picibanil (U.S. Pat. 
Sam rapamicin (U.S. pat. br. 4 885 171) ili u kombinaciji s picibanilom (U.S. pat. br. 4 401 653) također je pokazao i antitumorsku aktivnost.
As described above, in the liquefied gas treatment system and method according to the embodiment of the present invention, BOG generated during the transportation of cargo (including LNG) in the LNG carrier may be used as the fuel of the engine, or may be reliquefied, be returned to the cargo tank and be stored therein. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se plinovitu komponentu vraćenu u skladišni spremnik (11) ispušta iz skladišnog spremnika zajedno s otparenim plinom nastalim u skladišnom spremniku, te šalje u kompresor (13,13a,13b).
curing said extended release matrix formulation comprising at least a curing step of subjecting the extended release matrix formulation to a temperature which is at least the softening temperature of said polyethylene oxide for a time period of at least about 1 minute. 
barem jedan aktivni agens, i pri čemu je formulacija matrica s produljenim otpuštanjem stvrdnuta pri temperaturi od barem oko 60 °C u vremenskom periodu od oko 1 minute i ima snagu pucanja od barem oko 110 N kada je podvrgnut indentacijskom testu.
A pharmaceutical composition, characterized in comprising the compound, the pharmaceutically acceptable salt thereof or the stereoisomer thereof according to any one of claims 1-9 and one or more therapeutically active substances selected from TNF-a inhibitors, COX-1/COX-2 inhibitors, COX-2 inhibitors, glucocorticoids, inactivated antibodies for interleukin, regulators for chemotactic factor receptors, antagonists for histamine H1 receptors/antihistamines, antagonists for leukotriene D4 receptors, leukotriene antagonists, LTD4 antagonists, VLA-4 antagonists, corticosteroids, corticosteroids analogues, B2-agonists, theophylline, leukotriene biosynthetic inhibitors, epoxidase-2 inhibitors, phosphodiesterase type IV inhibitors, opioids analgesics, anticoagulants, B-blocking agents, B-adrenergic agonists, angiotensin converting enzyme inhibitors or HMG-CoA reducase inhibitors. 
Farmaceutski pripravak, naznačen time što sadrži spoj ili njegovu farmaceutski prihvatljivu sol prema bilo kojem od zahtjeva 1-4 i jednu ili više terapeutski aktivnih tvari odabranih iz skupa koji čine inhibitori TNF-a, inhibitori COX-1/COX-2, inhibitori COX-2, glukokortikoidi, inaktivirana protutijela za interleukin, regulatori za receptore kemotaktičkog faktora, antagonisti histaminskih HI receptora/antihistaminika, antagonisti leukotriena, antagonisti LTD4, antagonisti VLA-4, kortikosteroidi, analozi kortikosteroida, B2-agonisti, teofilin, biosintetski inhibitori leukotriena, inhibitori fosfodiesteraze tipa IV, opioidni analgetici, antikoagulanti, B fB-blokatori, B-adrenergički agonisti, inhibitori angiotenzin konvertirajućeg enzima ili inhibitori HMG-CoA reduktaze. O N
• R4 represents a C1-4 alkoxy carbonyl group, a C3-6 cycloalkyl carbonyl group, a benzoyl group or a C1-3 alkyl group optionally substituted by 1 to 4 substituents selected from a halogen atom or a hydroxyl group; and 
R4 predstavlja C,.4 alkoksikarbonilnu skupinu, C3.4 cikloalkilkarbonilnu skupinu, benzoilnu skupinu ili C,.; alkilnu skupinu, izborno supstituiranu s 1 do 4 supstituenta, koje se bira između atoma halogena ili hidroksilne skupine; i
first with a base and then with a compound of the formula CO2 to obtain the compound of formula (4), or salt thereof; and 
prvo sa bazom, a zatim sa spojem sa formulom CO2 kako bi se dobilo spoj sa formulom (4), ili njegova sol; i
Competitive radioligand binding assays with membrane preparations are performed in Millipore 96-well filtration plates with GF/C membrane filters that are pre-coated with 200 ul of 0.1% polyethylenimine (Sigma, St. Louis. 
Ispitivanja vezanja kompetitivnog radioliganda na membranskim preparatima provedena su na pločama za filtriranje s 96 jažica Millipore s GF/C membranskim filtrima prethodno obloženim s 200 ul 0,1 % polietilenimina (Sigma, St. Louis.
An assembly for implanting a balloon-expandable prosthetic aortic valve (10) in a patient's body, the assembly comprising: 
Sklop za ugradnju protetskog aortnog zgloba koji se može proširiti u balon u tijelu pacijenta, koji sadrži:
the second flexible wrapper is disposed outward of the first flexible wrapper; 
drugi fleksibilni omotač (40) se nalazi prema van u odnosu na prvi fleksibilni omotač (20);
A method for the treatment of cystic fibrosis, comprising administering to a subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound according to Formula I 
Farmaceutski pripravak naznačen time što sadrži farmaceutski prihvatljiv nosač 1 farmaceutski učinkovitu količinu spoja prema bilo kojem od zahtjeva 1-13.
The invention provides a pharmaceutical composition comprising an isolated antibody that comprises a heavy chain variable domain sequence comprising SEQ ID NO:3 and a light chain variable domain sequence comprising SEQ ID NO:4, and wherein said antibody specifically binds human IL-17 receptor A, for use in a method of treating psoriasis in an adult or juvenile patient having psoriasis, wherein the method comprises administering to said patient the pharmaceutical in a single or divided dose of about 70 to about 300 mg antibody per dose administered at time "0" (the first administration), at one week post time "0", and then administered every two weeks following the week one administration. IL-17 Receptor "A" 
Farmaceutska formulacija, koja sadrži vodenu otopinu pufera glutaminske kiseline i protutijela koje sadrži sekvencu varijabilne domene teškog lanca koja obuhvaća SEQ ID NO:3 i sekvencu varijabilne domene lakog lanca koja obuhvaća SEQ ID NO:4, naznačena time da se navedeno protutijelo specifično veže na ljudski receptor A za IL-17, te što: a) navedena formulacija sadrži glutaminsku kiselinu u koncentraciji od 5-30 mM + 0,2 mM; b) navedena formulacija ima pH 4,5-5,2 + 0,2; c) navedena formulacija dalje sadrži 2-4% prolin (mas/v) i 0,005-0,02% (mas/v) polisorbat 20; d) navedeno protutijelo ima koncentraciju od 100 do 150 mg/ml.
The method according to claim 1, characterized in that said second gasket (19) comprises a waterproof film of thermoplastic hot-melt adhesive, said sealing step (103) comprising the adhesion, so as to form a waterproof seal, of said waterproof film so as to straddle said lasting margins (18) and said first gasket (16). 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da navedena druga brtva (19) sadrži vodonepropusni tanki sloj termoplastičnog taljivog ljepila, navedena faza brtvenog spajanja (103) sastoji se od prianjanja navedenog vodonepropusnog tankog sloja na način da prekrije navedene prepuste za navlačenje (18) i navedenu prvu brtvu (16) radi dobivanja vodonepropusnog spoja.
The station according to claim 1, wherein each cell comprises a reflective surface arranged to face the respective pipe for at least half an angular extension of an outer cylindrical surface of the respective pipe. 
Stanica prema patentnom zahtjevu 1 ili 2, naznačena time da stanica (5) sadrži reflektivnu površinu (15) dizajniranu da je okrenuta prema cijevi (3) za najmanje polovinu kutnog produžetka odnosne vanjske cilindrične površine (2a).
Dispensing scoops, sampling scoops, buckets and covers; batch mixing container; syrup pump; mass pump; jet cooker; holding tank; mixing tank; starch moulding machine; starch moulding trays; drying chamber; product trays and covers; polishing drum. 
Dispenzer lopatica, lopatica za uzimanje uzoraka, kante i poklopci; posuda za mješanje jedne grupe; pumpa za sirup; pumpa za upumpavanje mase; aparat za ravnomjerno kuhanje sa mlaznicama; rezervoar za čuvanje; rezervoar za mješanje; stroj za kalupljenje škroba; posude za kalupljenje škroba; komora za sušenje; posude i prekrivači za proizvod; bubanj za poliranje.
The Journal of clinical investigation 119, 2317-2329 (2009). A therapeutic agent for use in a method of treating tendon damage or increasing tendon tensile strength, wherein the therapeutic agent is miR-29, a mimic thereof, or a precursor of either. 
Terapeutsko sredstvo, naznačeno time, da se upotrebljava u postupku liječenja oštećenja tetive ili u postupku povećanja vlačne čvrstoće tetive, pri čemu se kod terapeutskog sredstva radi o miR-29, o njegovom mimetiku ili o preteči jednog od oba dva.
two light chains and two heavy chains of an antibody, which specifically binds to a first antigen and comprises two Fab fragments; 
dva slaba lanca i dva jaka lanca protutijela koje se specifično veže na prvi antigen i sadrži dva Fab-fragmenta;
The method according to claim 10, in which the heat generated through operation of the mixed reactor is used for the thermal activation and/or for the evaporation of the water. 
Postupak u skladu s patentnim zahtjevom 5, naznačen time što se toplina nastala prilikom rada miješanog reaktora upotrebljava za toplinsko aktiviranje i/ili za otparavanje vode.
and R6 are independently of each other chosen from the series consisting of hydrogen and (C1-C4)-alkyl; 
i R6 su međusobno neovisno odabrani iz niza koji čine vodik i (C1-C4)-alkil;